Searchable abstracts of presentations at key conferences in endocrinology

ea0099p596 | Late-Breaking | ECE2024

Unravelling mitotane resistance in adrenocortical carcinoma: exploring alterations in lipid metabolism

Hassany Mariam , Warde Kate , Feely Sarah , Cantini Giulia , Propato Arianna , Galtarossa Luca , Luconi Michaela , Dennedy Michael

Management of ACC is difficult. Diagnosis usually occurs at an advanced disease stage. Resection of localised disease offers a potential cure, but recurrence is common (75-85% of cases). For the treatment of unresectable/metastatic disease, mitotane is the only approved drug, alongside M-EDP chemotherapy. Mitotane has a narrow therapeutic window and is poorly tolerated. Additionally, ACC is a heterogenous disease regarding phenotype, genotype, disease progression and resistanc...